WOONSOCKET, R.I. – CVS Health has announced a major initiative to improve access to more affordable fertility treatments across the U.S. through its CVS Specialty Pharmacy at its 9,000 community pharmacy locations. This move is part of a broader collaboration with the Trump administration’s TrumpRx Fertility program, which aims to reduce the cost of fertility medications and make them more accessible to Americans struggling with infertility.
CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (IVF) drug to bring the price of the medicine down by 84%.
CVS Specialty Pharmacy has a team of dedicated specialist pharmacists focused on fertility treatments, helping people use treatments safely and effectively. In addition, CVS Specialty Pharmacy will help people understand their fertility benefit and assess their financial options.
“Fertility medications often require special administration and high-touch expertise. We are proud to join the President to help make every step of the journey as simple as possible for families by providing nationwide access,” said Lucille Accetta, senior vice president and chief pharmacy officer, CVS Health. “We are committed to being America’s most trusted health care company as we strive to continually improve affordability and access to medicine for families everywhere.
“We are uniquely built to help deliver solutions like this with our clinical specialization, convenient locations, and ability to help people navigate to the lowest possible cost. As the Administration looks to provide more affordable fertility treatments to all Americans, CVS Specialty has the expertise in fertility and the industry relationships to deliver on the promise of the TrumpRx solution.”
This announcement represents another example of how CVS Health is expanding affordability for customers by leveraging its strengths in pharmacy and improving access through multiple delivery channels in healthcare, as CVS Health also done with GLP-1 drugs.
CVS anticipates the program will be available in January 2026. The company added as its gets closer to the launch date, it will provide additional information on how to use the platform to access fertility medicines.
